24 May 2013
Keywords: topotarget, savene, sees, strong, ph, i/ii, data
Article | 04 July 2005
Danish drugmaker TopoTarget AS says that Savene (dexrazoxane) has demonstrated a 97% success rate in a multicenter Phase II/III trial
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 August 2005
23 May 2013
© 2013 thepharmaletter.com